海正藥業(600267.SH):擬以5000萬元參與吉盛澳瑪增資
格隆匯12月27日丨海正藥業(600267.SH)公佈,南京吉盛澳瑪生物醫藥有限公司(簡稱“吉盛澳瑪”)成立於2021年,產品主要適應症包括過敏性鼻炎、過敏性皮炎、呼吸道感染、疫苗佐劑等,為支持其自身創新藥的研發,吉盛澳瑪近期計劃融資不超過1億元。鑑於吉盛澳瑪管線產品應用疾病領域符合公司發展戰略,為促進與吉盛澳瑪合作及推進公司自身創新藥發展,同意公司以5,000萬元自籌資金參與吉盛澳瑪本輪增資,若吉盛澳瑪此輪融資金額全部認購完畢,公司將持有吉盛澳瑪10.4167%股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.